Celcuity Inc. (CELC) on Tuesday released detailed results from the PIK3CA-mutated cohort of its Phase 3 VIKTORIA-1 trial, and the numbers are impressive. The company's experimental drug gedatolisib, when combined with other therapies, significantly outperformed the current standard of care in patients with a specific type of advanced breast cancer.

Gedatolisib Outperformed Comparator Regimen

The gedatolisib-triplet regimen—which combines gedatolisib with palbociclib and fulvestrant—delivered a statistically significant improvement in progression-free survival compared with alpelisib plus fulvestrant. Patients on the triplet therapy had a median progression-free survival of 11.1 months, versus just 5.6 months for the comparator arm. That's essentially double the time before the disease worsened.

Celcuity said the treatment reduced the risk of disease progression or death by 50%, based on a hazard ratio of 0.50. The objective response rate—the percentage of patients whose tumors shrank or disappeared—was 48.9% for the triplet, compared with 26.0% for alpelisib plus fulvestrant. And when tumors did respond, they stayed under control longer: the median duration of response was 15.7 months for the triplet versus 7.5 months for the comparator.

The company also reported encouraging results for the gedatolisib-doublet regimen (gedatolisib plus fulvestrant without palbociclib). Median progression-free survival was 11.3 months, again more than double the 5.6 months for alpelisib plus fulvestrant. The doublet achieved an objective response rate of 35.7% and a median duration of response of 24.2 months—a particularly striking number.

Trial Establishes Several Development Milestones

Celcuity noted that VIKTORIA-1 is the first Phase 3 study to demonstrate superiority of one PI3K/AKT/mTOR pathway inhibitor over another in this patient population. The 11.1-month median progression-free survival for the triplet is the highest ever reported in a Phase 3 study evaluating a second-line endocrine therapy-containing regimen for HR-positive, HER2-negative advanced breast cancer. Similarly, the 48.9% objective response rate is the highest reported in a Phase 3 trial of a second-line endocrine therapy-based regimen in this setting.

Celcuity Regulatory Filings Planned

Overall survival data are still immature, but Celcuity said both the triplet and doublet arms showed promising trends on that key secondary endpoint. The company plans to submit the VIKTORIA-1 data to the U.S. Food and Drug Administration as part of a supplemental New Drug Application and intends to seek approvals from additional regulatory agencies afterward.

Separately, the FDA has granted Priority Review to Celcuity's New Drug Application for gedatolisib in patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer, with a Prescription Drug User Fee Act target action date of July 17, 2026. That's a separate indication from the PIK3CA-mutated population reported today, but it underscores the drug's potential across multiple patient groups.

CELC Price Action: Celcuity shares were down 25.03% at $92.18 at the time of publication on Tuesday. The sharp drop may reflect profit-taking after recent gains or market concerns about the competitive landscape, but the data itself is undeniably strong.